Product Description
JS-005 is being developed by Shanghai Junshi Bioscience for the treatment of Active Ankylosing Spondylitis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05212051?term=JS-005&draw=2&rank=2)
Mechanisms of Action: IL17A Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Junshi Biosciences
Company Location:
Company Founding Year: None
Additional Commercial Interests: Fosun
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Psoriasis
Phase 2: Spondylitis, Ankylosing
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05975268 |
JS005-005-III-PsO | P3 |
Completed |
Psoriasis |
2025-08-20 |
2025-12-17 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06732973 |
JS005-007-BE | P1 |
Completed |
Healthy Volunteers |
2025-06-06 |
2025-12-17 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
CTR20240026 |
CTR20240026 | P2 |
Active, not recruiting |
Spondylitis, Ankylosing |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/05/2025 |
News Article |
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis |